RHINOCORT ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHINOCORT ALLERGY (RHINOCORT ALLERGY).
Budesonide is a corticosteroid with potent anti-inflammatory activity. It inhibits multiple inflammatory cell types and mediators, reducing nasal congestion, sneezing, and rhinorrhea.
| Metabolism | Budesonide undergoes extensive first-pass metabolism in the liver via CYP3A4 to form two major metabolites (16α-hydroxyprednisolone and 6β-hydroxybudesonide) which have minimal glucocorticoid activity. |
| Excretion | Primarily hepatic metabolism via CYP3A4, followed by renal excretion of inactive metabolites (approximately 80% in urine) and biliary/fecal elimination (20%). Less than 2% unchanged drug in urine. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours. Intranasal administration results in minimal systemic absorption, so clinical effect duration is determined by local tissue retention rather than plasma half-life. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.0 L/kg. This indicates extensive tissue distribution, but clinical relevance is limited due to primarily local action. |
| Bioavailability | Intranasal administration results in low systemic bioavailability due to limited absorption and first-pass metabolism. Systemic bioavailability is less than 1% (approximately 0.1-0.5% of the administered dose). |
| Onset of Action | Intranasal: Onset of symptomatic relief begins within 10-12 hours after first dose, with maximum effect achieved after 1-2 weeks of regular use. |
| Duration of Action | Intranasal: Duration of clinical effect is dose-dependent, typically 24 hours after a single dose. Regular once-daily dosing provides sustained symptom control due to local anti-inflammatory effects. |
1-2 sprays per nostril once daily; intranasal route.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 6-12 years: 1 spray per nostril once daily; maximum 1 spray/nostril/day. Not recommended for children under 6 years. |
| Geriatric use | Same as adult dosing; no specific dose adjustment necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RHINOCORT ALLERGY (RHINOCORT ALLERGY).
| Breastfeeding | Excreted in breast milk in low amounts. M/P ratio not established for intranasal route. At therapeutic intranasal doses, systemic absorption is negligible; considered compatible with breastfeeding. |
| Teratogenic Risk | Category B. Inhaled budesonide at recommended doses is not associated with increased risk of major malformations. First trimester: no increased risk in human studies. Second and third trimesters: potential for fetal growth restriction with high systemic exposure; minimal risk at intranasal doses. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product","Untreated nasal mucosal infections (e.g., herpes simplex)"]
| Precautions | ["Immunosuppression and increased susceptibility to infections","Hypothalamic-pituitary-adrenal axis suppression with long-term use","Local effects including epistaxis, nasal ulceration, and Candida albicans infection","Potential for growth suppression in pediatric patients","Ocular effects such as glaucoma and cataracts"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal adrenal suppression if high doses or prolonged use. Fetal growth assessed by ultrasound if high cumulative exposure. No routine monitoring required for standard intranasal dosing. |
| Fertility Effects | No evidence of impairment of fertility in animal studies or human data. Inhaled corticosteroids at typical doses do not adversely affect fertility. |